BidaskClub downgraded shares of Bruker (NASDAQ:BRKR) from a strong-buy rating to a buy rating in a report released on Thursday.

BRKR has been the topic of a number of other reports. Zacks Investment Research raised shares of Bruker from a hold rating to a buy rating and set a $37.00 price target on the stock in a research note on Wednesday, November 8th. Bank of America raised shares of Bruker from an underperform rating to a neutral rating and set a $34.00 price target on the stock in a research note on Friday, November 3rd. Cowen reaffirmed a hold rating and set a $29.00 price target on shares of Bruker in a research note on Friday, November 3rd. BTIG Research began coverage on shares of Bruker in a research note on Friday, January 5th. They set a buy rating and a $42.00 price target on the stock. Finally, JPMorgan Chase & Co. raised shares of Bruker from an underweight rating to a neutral rating and set a $28.00 price target on the stock in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $32.38.

Shares of Bruker (BRKR) traded up $0.47 on Thursday, reaching $34.97. 564,300 shares of the company’s stock traded hands, compared to its average volume of 513,556. The company has a quick ratio of 1.60, a current ratio of 2.60 and a debt-to-equity ratio of 0.65. The firm has a market cap of $5,440.03, a PE ratio of 37.20, a P/E/G ratio of 2.63 and a beta of 1.12. Bruker has a 12 month low of $21.83 and a 12 month high of $36.53.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.02. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The business had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. During the same period in the prior year, the company posted $0.32 EPS. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. sell-side analysts anticipate that Bruker will post 1.19 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Investors of record on Monday, December 4th were given a $0.04 dividend. The ex-dividend date of this dividend was Friday, December 1st. This represents a $0.16 annualized dividend and a dividend yield of 0.46%. Bruker’s dividend payout ratio is presently 17.02%.

Several institutional investors have recently added to or reduced their stakes in the stock. Utah Retirement Systems boosted its position in shares of Bruker by 1.1% in the 2nd quarter. Utah Retirement Systems now owns 19,189 shares of the medical research company’s stock worth $553,000 after buying an additional 200 shares in the last quarter. Tudor Investment Corp ET AL boosted its position in shares of Bruker by 1.5% in the 2nd quarter. Tudor Investment Corp ET AL now owns 15,980 shares of the medical research company’s stock worth $461,000 after buying an additional 242 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after buying an additional 331 shares in the last quarter. Advisory Services Network LLC boosted its position in shares of Bruker by 6.3% in the 2nd quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock worth $197,000 after buying an additional 406 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bruker by 11.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after buying an additional 467 shares in the last quarter. Institutional investors and hedge funds own 65.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Bruker (BRKR) Downgraded by BidaskClub to “Buy”” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/01/15/bruker-brkr-downgraded-by-bidaskclub-to-buy.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.